Usage of Cookies
We use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about our use of cookies can be found in our privacy policy. If you continue to use this website we will assume that you agree with the usage of cookies. You can prevent cookies from being installed or delete them from your computer. How this works, is explained in our privacy policy. Imprint

NOXXON's proprietary technology generates compounds we refer to as Spiegelmers*, which are a new class of therapeutics designed to combine the benefits of small chemical molecules and biologicals.

NOXXON's proprietary technology offers a set of significant advantages over existing drug classes:

  • High affinity and specificity for targets with demonstrated activity on chemokines in clinical trials
  • Can be manufactured chemically and do not require complex biological production processes
  • High bio-stability and immunologically passive
  • Good safety and tolerability profile based on results from more than 10 trials in over 300 human subjects

Spiegelmers use Mirror-image (L-stereoisomer) chemistry to build injectable oligonucleotide (RNA or DNA) therapeutics that directly bind and neutralize protein targets in the extracellular space.

NOXXON has established optimized production and quality control methods in-house and with partners for production in accordance with good manufacturing practices.